Repligen (RGEN) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
- Market cap
- $10.7B
- As of Nov 13, 2026
- P/E
- -894.92x
- Trailing twelve months
- P/B
- 5.13x
- Latest reported equity
- P/S
- 13.34x
- Trailing twelve months
- ROE
- -0.6%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $10.7B
- As of Nov 13, 2026
- P/E
- -894.92x
- Trailing twelve months
- P/B
- 5.13x
- Latest reported equity
- P/S
- 13.34x
- Trailing twelve months
- ROE
- -0.6%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-894.92x
Net loss — not comparable
P/B
5.13x
P/S
13.34x
Earnings and dividend metrics▾
Earnings
EPS
-$0.19
Earnings per share
BPS
$32.69
Book value per share
ROE
-0.6%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $0.19 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $32.69 of net assets.
- ROE — shareholder equity shrank by 0.6% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 10.6% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $189M+10.6%
$155M
Jul–Sep '24
$189M
Jul–Sep '25
$209M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 30, 2026.
- Earnings per share decreased 361.5% from the same quarter a year earlier.
- Revenue increased 10.6% from the same quarter a year earlier.
- Operating income decreased 276.5% from the same quarter a year earlier.
- Net income decreased 353.3% from the same quarter a year earlier.
Filed Oct 30, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Douglass Brian RobbCHIEF PRODUCT OFFICER · Oct 6, 2026Grant or award700 shares · $0Avg. price $08,685 shares held after
- Loeillot OlivierChief Executive Officer · Oct 5, 2026Open-market sale5,535 shares · $1.0MAvg. price $187.290745,788 shares held after
Show 2 price lots
- 4,202 shares × $190$798K
- 1,333 shares × $178.75$238K
- Loeillot OlivierChief Executive Officer · Oct 5, 2026Option exercise4,202 shares · $651KAvg. price $154.9649,990 shares held after
- Loeillot OlivierChief Executive Officer · Oct 2, 2026Shares withheld for taxes1,248 shares · $227KAvg. price $181.747,121 shares held after
- Garland Jason KCFO · Sep 25, 2026Shares withheld for taxes421 shares · $80KAvg. price $189.6818,408 shares held after
- Loeillot OlivierChief Executive Officer · Sep 24, 2026Open-market sale12,946 shares · $2.5MAvg. price $19048,369 shares held after
Show 2 price lots
- 8,404 shares × $190$1.6M
- 4,542 shares × $190$863K
- Loeillot OlivierChief Executive Officer · Sep 24, 2026Option exercise12,946 shares · $2.0MAvg. price $155.1074
Show 2 price lots
- 8,404 shares × $154.96$1.3M
- 4,542 shares × $155.38$706K
- Loeillot OlivierChief Executive Officer · Sep 21, 2026Open-market sale5,426 shares · $977KAvg. price $18048,369 shares held after
- Loeillot OlivierChief Executive Officer · Sep 21, 2026Option exercise5,426 shares · $769KAvg. price $141.7953,795 shares held after
- Loeillot OlivierChief Executive Officer · Sep 4, 2026Open-market sale3,035 shares · $504KAvg. price $165.948,369 shares held after
- Loeillot OlivierChief Executive Officer · Sep 3, 2026Shares withheld for taxes2,842 shares · $482KAvg. price $169.6151,404 shares held after
- Hughes ViolettaCHIEF ACCOUNTING OFFICER · Sep 1, 2026Shares withheld for taxes277 shares · $47KAvg. price $170.026,331 shares held after
- Loeillot OlivierChief Executive Officer · Aug 20, 2026Open-market sale5,426 shares · $977KAvg. price $18054,246 shares held after
- Loeillot OlivierChief Executive Officer · Aug 20, 2026Option exercise5,426 shares · $769KAvg. price $141.7959,672 shares held after
- Hughes ViolettaCHIEF ACCOUNTING OFFICER · Mar 5, 2026Grant or award2,466 shares · $0Avg. price $06,608 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Repligen (RGEN) stock information
NASDAQ
Repligen (RGEN) is listed on NASDAQ. Its market capitalization is about $10.7B. On trailing-twelve-month earnings the P/E ratio is -894.92, and the P/B ratio is 5.13. Return on equity is -0.6%. These figures are computed in-house from official filings and are reference information only.
Repligen — frequently asked questions
- What is the P/E ratio of Repligen (RGEN)?
- On a trailing-twelve-month basis, RGEN trades at a P/E ratio of -894.92. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Repligen?
- RGEN has a market capitalization of about $10.7B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.